Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about msa: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet. View on Wiki →
| Phase 1/2 focus | Majority of trials in early phases, limited Phase 3 activity |
| Synuclein targeting | Multiple programs targeting alpha-synuclein aggregation or propagation |
| Neuroprotective approaches | Broad-spectrum neuroprotection given rapid progression |
| Symptomatic trials | Autonomic dysfunction management (orthostatic hypotension, urinary dysfunction) |
| Alpha-synuclein modulation | Programs from biotech companies targeting alpha-synuclein aggregation |
| Neuroprotection | Preserving autonomic and motor neurons given rapid progression |
| Autonomic dysfunction | Orthostatic hypotension, bladder/bowel dysfunction primary causes of morbidity |
| Myelin protection | Oligodendrocyte dysfunction is central to MSA pathology |
| Biomarker development | Neurofilament light chain (NfL), alpha-synuclein seed amplification assays |
| Rapid progression | Shorter window for intervention than PD or AD |
| Diagnostic delay | Average 3-5 years from symptom onset to diagnosis |
| Heterogeneity | MSA-P vs MSA-C phenotypes complicate trial design |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
Knowledge base pages for this entity
flowchart TD
N0["MSA"]
N1["synucleinopathies"]
N0 -->|"contributes to"| N1
N2["alpha_synuclein"]
N2 -->|"causes"| N0
N3["NEURODEGENERATION"]
N0 -->|"associated with"| N3
N4["SCHIZOPHRENIA"]
N0 -->|"associated with"| N4
N5["HAND"]
N5 -->|"associated with"| N0
N6["ALS"]
N6 -->|"associated with"| N0
N7["AUTISM"]
N7 -->|"associated with"| N0
N8["DEPRESSION"]
N8 -->|"associated with"| N0
N9["EPILEPSY"]
N9 -->|"associated with"| N0
N10["PARKINSON"]
N0 -->|"co discussed"| N10
N11["PARKINSON'S"]
N0 -->|"co discussed"| N11
classDef gene fill:#1a3a2a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#1a2a3a,stroke:#4fc3f7,color:#e0e0e0
classDef disease fill:#3a1a1a,stroke:#ef5350,color:#e0e0e0
classDef pathway fill:#2a1a3a,stroke:#ce93d8,color:#e0e0e0
classDef mechanism fill:#2a2a1a,stroke:#ffd54f,color:#e0e0e0
classDef therapeutic fill:#1a2a2a,stroke:#26a69a,color:#e0e0e0
class N1 disease
class N2 protein| Target | Relation | Type | Str |
|---|---|---|---|
| synucleinopathies | contributes_to | disease | 0.76 |
| NEURODEGENERATION | associated_with | entity | 0.60 |
| SCHIZOPHRENIA | associated_with | entity | 0.60 |
| PARKINSON | co_discussed | entity | 0.50 |
| PARKINSON'S | co_discussed | entity | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| alpha_synuclein | causes | protein | 0.72 |
| HAND | associated_with | entity | 0.60 |
| ALS | associated_with | entity | 0.60 |
| AUTISM | associated_with | entity | 0.60 |
| DEPRESSION | associated_with | entity | 0.60 |
| EPILEPSY | associated_with | entity | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
No analyses mention this entity
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||